세계의 피하 피임 임플란트 시장 - 규모, 점유율, 동향 분석 보고서 : 제품별, 유통 채널별, 지역별 부문 예측(2025-2030년)

Subdermal Contraceptive Implants Market Growth & Trends:

The global subdermal contraceptive implants market size is estimated to reach USD 1.74 billion by 2030, registering to grow at a CAGR of 7.61% from 2025 to 2030 according to a new report by Grand View Research, Inc. Introduction of several modern contraceptives in the market, growing awareness about various birth control methods, and high per capita income are some of the key factors driving the market for subdermal implants for birth control.

According to the Guttmacher Institute, in 2014, approximately 20 million women needed publicly funded contraceptive services. According to CDC, in 2017, nearly 46.9 million women in the U.S. were using at least one method of contraception. Subdermal implant is a long-term birth control option for women. Subdermal implants for contraception are in the form of polymer capsules or rods placed under the skin. The progestational hormone is released at a slow and stable rate, providing effective contraception for 1-5 years.

Publicly funded family planning services help women avoid or plan pregnancies. In 2012, the South Carolina Department of Health and Human Services (SCDHHS) revised the cost associated with Medicaid payment policy for immediate postpartum insertion of Long-Acting Reversible Contraception (LARC). Under this new reimbursement policy, providers are allowed to bill for the insertion procedure and the cost of an IUD or an implant, in addition to the Diagnosis Related Group (DRG) by using J-codes with a family planning modifier.

Implants are the most widely used contraceptive methods by women in sub-Saharan Africa owing to public-private partnerships between manufacturers, donors, governments, and international agencies, which helps lower commodity cost and increase product availability. Contraceptive usage has increased in South Africa, Malawi, and Rwanda. According to PLOS.org, in Malawi, the use of the Long-acting Reversible Contraception (LARC) method reached 10.21% in urban areas in 2016 and 9.66% in rural areas. In 2012, an initiative called Family Planning 2020 (FP2020) was launched to give 120 million women access to modern contraceptive methods by 2020.

Subdermal Contraceptive Implants Market Report Highlights:

• Etonogestrel implants dominated the market and accounted for a share of 64.73% in 2024. The driving factors are rising unintended pregnancies and unsafe abortions.
• Hospital dominated the market and accounted for a share of 54.37% in 2024. Hospitals provide a comprehensive environment for patients, offering a wide range of services including tests, consultations, and procedures, which drive segment growth.
• North America subdermal contraceptive implants market dominated the market with a market share of 64.91% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Secondary Sources
  • 1.4.2. List of Primary Sources
  • 1.4.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product Outlook
  • 2.2.2. Distribution Channel Outlook
  • 2.2.3. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Subdermal Contraceptive Implants Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Awareness of family planning
    • 3.2.1.2. Demand for Long-Acting Reversible Contraceptives (LARCs)
    • 3.2.1.3. Technological advancements and product improvements
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. Side effects and health concerns
  • 3.2.3. Industry Challenges and Opportunity Analysis
• 3.3. Subdermal Contraceptive Implants Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Subdermal Contraceptive Implants Market: Product Estimates & Trend Analysis

• 4.1. Definition and Scope
• 4.2. Product Market Share Analysis, 2024 & 2030
• 4.3. Segment Dashboard
• 4.4. Subdermal Contraceptive Implants Market: By Product, 2018 to 2030
  • 4.4.1. Etonogestrel Implant
    • 4.4.1.1. Etonogestrel implant market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Levonorgestrel Implant
    • 4.4.2.1. Levonorgestrel implant market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Subdermal Contraceptive Implants Market: Distribution Channel Estimates & Trend Analysis

• 5.1. Definition and Scope
• 5.2. Distribution Channel Market Share Analysis, 2024 & 2030
• 5.3. Segment Dashboard
• 5.4. Subdermal Contraceptive Implants Market: By Distribution Channel, 2018 to 2030
  • 5.4.1. Hospital
    • 5.4.1.1. Hospital market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Gynecology Clinics
    • 5.4.2.1. Gynecology clinics market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Community Health Care Centers
    • 5.4.3.1. Community health care centers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Others
    • 5.4.4.1. Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Subdermal Contraceptive Implants Market: Regional Estimates & Trend Analysis by Region, Product

• 6.1. Definition and Scope
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Subdermal Contraceptive Implants Market Share, By Region, 2024 & 2030 (USD Million)
• 6.4. North America
  • 6.4.1. North America Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. U.S. Key Country Dynamics
    • 6.4.2.2. Regulatory Landscape/Reimbursement Scenario
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Canada Key Country Dynamics
    • 6.4.3.2. Regulatory Landscape/Reimbursement Scenario
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Mexico Key Country Dynamics
    • 6.4.4.2. Regulatory Landscape/Reimbursement Scenario
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. UK Key Country Dynamics
    • 6.5.2.2. Regulatory Landscape/Reimbursement Scenario
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. U.K. Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Germany Key Country Dynamics
    • 6.5.3.2. Regulatory Landscape/Reimbursement Scenario
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. France Key Country Dynamics
    • 6.5.4.2. Regulatory Landscape/Reimbursement Scenario
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Italy Key Country Dynamics
    • 6.5.5.2. Regulatory Landscape/Reimbursement Scenario
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Spain Key Country Dynamics
    • 6.5.6.2. Regulatory Landscape/Reimbursement Scenario
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Denmark Spain Key Country Dynamics
    • 6.5.7.2. Regulatory Landscape/Reimbursement Scenario
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Denmark Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Sweden Key Country Dynamics
    • 6.5.8.2. Regulatory Landscape/Reimbursement Scenario
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Sweden Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Norway Key Country Dynamics
    • 6.5.9.2. Regulatory Landscape/Reimbursement Scenario
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Norway Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. China
    • 6.6.2.1. China Key Country Dynamics
    • 6.6.2.2. Regulatory Landscape/Reimbursement Scenario
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. China Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. Japan
    • 6.6.3.1. Japan Key Country Dynamics
    • 6.6.3.2. Regulatory Landscape/Reimbursement Scenario
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. Japan Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. India Key Country Dynamics
    • 6.6.4.2. Regulatory Landscape/Reimbursement Scenario
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. South Korea Key Country Dynamics
    • 6.6.5.2. Regulatory Landscape/Reimbursement Scenario
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. South Korea Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Australia Key Country Dynamics
    • 6.6.6.2. Regulatory Landscape/Reimbursement Scenario
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. Australia Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Thailand Key Country Dynamics
    • 6.6.7.2. Regulatory Landscape/Reimbursement Scenario
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Thailand Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Brazil Key Country Dynamics
    • 6.7.2.2. Regulatory Landscape/Reimbursement Scenario
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Argentina Key Country Dynamics
    • 6.7.3.2. Regulatory Landscape/Reimbursement Scenario
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Middle East and Africa (MEA)
  • 6.8.1. Middle East and Africa Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. South Africa Key Country Dynamics
    • 6.8.2.2. Regulatory Landscape/Reimbursement Scenario
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Saudi Arabia Key Country Dynamics
    • 6.8.3.2. Regulatory Landscape/Reimbursement Scenario
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. UAE Key Country Dynamics
    • 6.8.4.2. Regulatory Landscape/Reimbursement Scenario
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Kuwait Key Country Dynamics
    • 6.8.5.2. Regulatory Landscape/Reimbursement Scenario
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis by Key Market Participants
• 7.2. Company Categorization
• 7.3. Company Market Share Analysis
• 7.4. Company Heat Map Analysis
• 7.5. Strategy Mapping
• 7.6. Company Profiles
  • 7.6.1. Merck & Co., Inc.
    • 7.6.1.1. Participant's Overview
    • 7.6.1.2. Financial Performance
    • 7.6.1.3. Product Benchmarking
    • 7.6.1.4. Recent Developments
  • 7.6.2. Shanghai Dahua Pharmaceutical Co., Ltd.
    • 7.6.2.1. Participant's Overview
    • 7.6.2.2. Financial Performance
    • 7.6.2.3. Product Benchmarking
    • 7.6.2.4. Recent Developments
  • 7.6.3. Bayer AG
    • 7.6.3.1. Participant's Overview
    • 7.6.3.2. Financial Performance
    • 7.6.3.3. Product Benchmarking
    • 7.6.3.4. Recent Developments
  • 7.6.4. Baxter
    • 7.6.4.1. Participant's Overview
    • 7.6.4.2. Financial Performance
    • 7.6.4.3. Product Benchmarking
    • 7.6.4.4. Recent Developments
  • 7.6.5. BD
    • 7.6.5.1. Participant's Overview
    • 7.6.5.2. Financial Performance
    • 7.6.5.3. Product Benchmarking
    • 7.6.5.4. Recent Developments
  • 7.6.6. Gerresheimer AG
    • 7.6.6.1. Participant's Overview
    • 7.6.6.2. Financial Performance
    • 7.6.6.3. Product Benchmarking
    • 7.6.6.4. Recent Developments
  • 7.6.7. Pfizer, Inc.
    • 7.6.7.1. Participant's Overview
    • 7.6.7.2. Financial Performance
    • 7.6.7.3. Product Benchmarking
    • 7.6.7.4. Recent Developments
  • 7.6.8. Novartis AG
    • 7.6.8.1. Participant's Overview
    • 7.6.8.2. Financial Performance
    • 7.6.8.3. Product Benchmarking
    • 7.6.8.4. Recent Developments
  • 7.6.9. SCHOTT
    • 7.6.9.1. Participant's Overview
    • 7.6.9.2. Financial Performance
    • 7.6.9.3. Product Benchmarking
    • 7.6.9.4. Recent Developments
  • 7.6.10. Lilly
    • 7.6.10.1. Participant's Overview
    • 7.6.10.2. Financial Performance
    • 7.6.10.3. Product Benchmarking
    • 7.6.10.4. Recent Developments